drugset / Trial / NCT02111044

Phase II Study With ITF2984 in Acromegalic Patients

NCT02111044

Phase 2 Completed 48 enrolled Italfarmaco
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to investigate in acromegalic patients the effect of different doses of ITF2984 on GH and IGF-1 concentrations and to investigate safety and tolerability of three different doses of ITF2984.

Timeline

Start
2014-04
Primary completion
2016-02
Completion
2016-02

Drugs

EvaluationDrugModalityDoseRoute
Subject ITF2984 Other / unclassified 500 ug Subcutaneous
Subject ITF2984 Other / unclassified 1000 ug Subcutaneous
Subject ITF2984 Other / unclassified 2000 ug Subcutaneous
Comparator Octreotide Peptide 100 ug Subcutaneous

Indications